drugset / Trial / NCT06308523
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
The study will be a single center, double-blind, randomized, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to healthy Chinese participants.
Timeline
- Start
- 2024-03-18
- Primary completion
- 2024-05-13
- Completion
- 2024-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP303 | Unknown | 150 ug | Oral |
| Subject | AP303 | Unknown | 300 ug | Oral |
Indications
No indication recorded.